Target intelligence / Profile preview

Cholinergic presynaptic terminal receptor

Molecular classification
G protein-coupled receptor, Ion channel, Receptor
01

Overview

Cholinergic presynaptic terminal receptor refers to a functional group of receptors located on the presynaptic membranes of cholinergic neurons that modulate the release of acetylcholine (ACh). This group primarily includes muscarinic autoreceptors, specifically the M2 and M4 subtypes, which provide negative feedback to inhibit further neurotransmitter release via G protein-coupled signaling (UniProt P08172, P08173). Additionally, nicotinic autoreceptors, such as the alpha-7 and alpha-4-beta-2 subtypes, are present and often facilitate ACh release through ionotropic mechanisms (PubMed: 10674688). The terminal also expresses various heteroreceptors for other neurotransmitters, such as glutamate or GABA, which further fine-tune acetylcholine output. These receptors are essential for maintaining cholinergic homeostasis and are involved in cognitive processes, memory, and motor control (StatPearls: Physiology, Cholinergic Receptors). Dysregulation of these receptors is associated with neurodegenerative diseases like Alzheimer's and psychiatric conditions like schizophrenia. Pharmacological targeting of these receptors is a strategy used to enhance cholinergic tone or modulate neurotransmitter imbalance, though achieving subtype specificity remains a significant therapeutic challenge (PubMed: 15556490).

Other names
Presynaptic cholinergic receptorCholinergic autoreceptorPresynaptic muscarinic receptorPresynaptic nicotinic receptor
02

Mechanism of action

Modulation of acetylcholine release through the activation or inhibition of presynaptic autoreceptors (M2, M4, nAChRs) and heteroreceptors.

03

Biological functions

Signal transductionRegulation of neurotransmitter releaseSynaptic plasticityFeedback inhibition
04

Disease associations

Neurodegenerative diseaseAlzheimer's diseaseSchizophreniaCognitive impairmentParkinson's disease
05

Safety considerations

SLUDGE syndrome (Salivation, Lacrimation, Urination, Defecation, Gastrointestinal distress, Emesis)Cardiovascular instability (bradycardia or tachycardia)Cognitive side effects (confusion, hallucinations)Autonomic nervous system imbalance
06

Interacting drugs

Atropine

8 more in the full profile.

07

Biomarkers

Acetylcholine levels in cerebrospinal fluid[18F]F-A-85380 PET imaging[11C]AF-DX 384 PET imaging[11C]MP4A PET imaging

Beyond the preview

Go deeper on Cholinergic presynaptic terminal receptor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cholinergic presynaptic terminal receptor.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call